U

Universal Biosensors Inc
ASX:UBI

Watchlist Manager
Universal Biosensors Inc
ASX:UBI
Watchlist
Price: 0.014 AUD Market Closed
Market Cap: AU$4.2m

Net Margin

-293.3%
Current
Improving
by 10.8%
vs 3-y average of -304.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-293.3%
=
Net Income
AU$-17.5m
/
Revenue
AU$6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-293.3%
=
Net Income
AU$-17.5m
/
Revenue
AU$6m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Universal Biosensors Inc
ASX:UBI
4.2m AUD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.6B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
186.9B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
138.7B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.1B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
130.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.5B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.5B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.9B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
34th
Based on 4 004 companies
34th percentile
-293.3%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Universal Biosensors Inc
Glance View

Market Cap
4.2m AUD
Industry
Health Care

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.

UBI Intrinsic Value
0.054 AUD
Undervaluation 74%
Intrinsic Value
Price
U
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-293.3%
=
Net Income
AU$-17.5m
/
Revenue
AU$6m
What is Universal Biosensors Inc's current Net Margin?

The current Net Margin for Universal Biosensors Inc is -293.3%, which is above its 3-year median of -304.1%.

How has Net Margin changed over time?

Over the last 3 years, Universal Biosensors Inc’s Net Margin has increased from -301.2% to -293.3%. During this period, it reached a low of -637.3% on Mar 31, 2023 and a high of -93.9% on Mar 31, 2024.

Back to Top